Definium Therapeutics Stock Forecast
NASDAQ: DFTXHealth Care Medicinal Chemicals and Botanical Products USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DFTX analyst consensus
Consensus (18 analysts)
none
Avg. price target
$71.65+104.19%
- Strong buy 4
- Buy 14
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 18 Wall Street analysts covering Definium Therapeutics (2026-10-07), 18 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $71.65, with a high estimate of $91.00 and a low estimate of $55.00. The average target implies upside of 104.2% from the current price of $35.09.
The spread between the highest and lowest targets is 65.5%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for DFTX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 4 | 22% |
| Buy | 14 | 78% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $55.00 | +56.74% |
| Average target | $71.65 | +104.19% |
| High target | $91.00 | +159.33% |
How analysts view Definium Therapeutics's peers
| Company | Consensus | Price | Avg. target | Implied move |
|---|---|---|---|---|
| TRLV | strong_buy | 10.78 | $18.18 | +68.65% |